Developer docs
API playgroundTry for free, no card

Search company profiles

Talphera

Full company profile

uuid000048g

Namestring
Talphera
Legal namestring
Talphera, Inc.
Websiteurl
talphera.com
Company typeenum
Public
Founded yearint
2005
Descriptiontext

Talphera is a specialty pharmaceutical company that develops and commercializes therapies for medically supervised settings, primarily hospital intensive care units and perioperative environments. Originally founded in 2005 as AcelRx Pharmaceuticals and renamed Talphera in 2023 following the divestiture of its acute pain product DSUVIA, the company has refocused on regional anticoagulation and injectable drug delivery for critically ill patients.

The company's lead product candidate is Niyad (nafamostat mesylate), a lyophilized formulation of a broad-spectrum serine protease inhibitor positioned to be the first FDA-approved regional anticoagulant for the extracorporeal circuit during continuous renal replacement therapy (CRRT) and intermittent hemodialysis. Niyad has received FDA Breakthrough Device Designation and is in a registrational study (NEPHRO CRRT) enrolling 70 patients across up to 14 U.S. hospital ICUs, with PMA submission planned for 2026. Nafamostat's 8-minute half-life enables rapid clearance and predominantly extracorporeal activity, addressing bleeding-risk patients who cannot tolerate heparin. Additional candidates include LTX-608 (a nafamostat product for inflammatory and antiviral indications including COVID-19, DIC, ARDS, and acute pancreatitis) and two pre-filled syringe products (Fedsyra for ephedrine and PFS-02 for phenylephrine) developed in partnership with Laboratoire Aguettant.

Talphera generates revenue primarily through a 15% royalty on commercial net sales of DSUVIA following its 2023 divestiture to Alora Pharmaceuticals (75% on U.S. Department of Defense sales, plus up to $116.5 million in sales-based milestones). The company is pre-commercial on its own pipeline and funds operations through equity financings and royalty monetization, with a recent $29 million private placement led by CorMedix. End customers are anticipated to be hospital ICUs, nephrology departments, and perioperative care providers accessed through hospital pharmacy procurement and group purchasing organizations.

Short descriptiontext

Talphera is a specialty pharmaceutical company developing therapies for medically supervised settings, with lead candidate Niyad (nafamostat) positioned as the first FDA-approved regional anticoagulant for continuous renal replacement therapy in hospital ICUs. The company also holds royalty rights to the divested DSUVIA product.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Mateo, United States
HQ citystring
San Mateo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regional anticoagulants, renal replacement therapy, specialty pharmaceuticals, critically ill patients, medically supervised settings
Industry3 codes
PRIMARYHLAHAKAH
Renal Replacement Therapy Consumables (Bloodlines, Filters, Cartridges)
SECONDARYHLAIAIAI
Rare Renal & Nephrology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1DSUVIA Royalty
TypeLicensing Royalties
Description

Following divestment of DSUVIA to Alora Pharmaceuticals in April 2023, Talphera receives a 15% royalty on commercial net sales, a 75% royalty on net sales to the United States Department of Defense, and up to $116.5 million in sales-based milestone payments.

talphera.com
2Niyad (future commercial revenue)
TypeOne Time License
Description

Once FDA approved, Niyad would be commercialized as the first FDA-approved regional anticoagulant for the extracorporeal circuit in CRRT, targeting hospitals and ICUs. Currently in late-stage development with PMA submission planned for 2026.

talphera.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Niyad
Description

A lyophilized formulation of nafamostat mesylate positioned to be the first FDA-approved regional anticoagulant for use in the extracorporeal circuit during continuous renal replacement therapy (CRRT).

talphera.com
+4 more records
Core offering1 text field

Talphera is a specialty pharmaceutical company developing and commercializing innovative therapies for medically supervised settings. Its lead product candidate, Niyad (nafamostat mesylate), is a lyophilized formulation positioned to become the first FDA-approved regional anticoagulant for the extracorporeal circuit during continuous renal replacement therapy (CRRT) for patients who cannot tolerate heparin or have increased bleeding risk. The company also develops pre-filled syringe products (Fedsyra and PFS-02) for perioperative hypotension and retains royalty rights on the divested DSUVIA product.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Meta-analysis published in 2022 demonstrated significant safety and efficacy improvements over current standards of care for nafamostat use in extracorporeal circuit
+2 more records
Product overview1 text field

Talphera is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. The company's portfolio includes Niyad®, its lead product candidate (a lyophilized nafamostat formulation for regional anticoagulation in renal replacement therapy), LTX-608™ (a nafamostat-based candidate for inflammatory and antiviral applications), and two pre-filled syringe candidates (Fedsyra™ and PFS-02) developed in partnership with Laboratoire Aguettant. The company was formerly known as AcelRx Pharmaceuticals and renamed to Talphera following the 2023 divestment of its acute pain product DSUVIA.

Product and service4 records
1Niyad (nafamostat mesylate)
CategoryRegional Anticoagulant for Renal Replacement Therapy
Description

A lyophilized formulation of nafamostat mesylate positioned to be the first FDA-approved regional anticoagulant for the extracorporeal circuit during continuous renal replacement therapy (CRRT) or intermittent hemodialysis (IHD). It targets hospital intensive care units and nephrology departments treating critically ill patients who cannot tolerate heparin or have increased bleeding risk.

2LTX-608
CategoryInflammatory and Antiviral Therapeutics
Description

A nafamostat-based product candidate being investigated for various indications including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis, leveraging nafamostat's anti-inflammatory and antiviral properties. Regulated as a pharmaceutical.

3Fedsyra
CategoryPerioperative Antihypotensive Injectable
Description

A 10 mL ready-to-use pre-filled syringe of ephedrine hydrochloride in development for the treatment of hypotension during general anesthesia. Developed in partnership with Laboratoire Aguettant to streamline care with waste reduction, time savings, and improved safety.

4PFS-02
CategoryPerioperative Antihypotensive Injectable
Description

A 10 mL ready-to-use pre-filled syringe of phenylephrine hydrochloride in development for the treatment of hypotension due to vasodilation. Developed in partnership with Laboratoire Aguettant as a ready-to-use alternative to vials and ampules.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Partnership with France-based pharmaceutical company Laboratoire Aguettant for the development of pre-filled syringe product candidates Fedsyra (ephedrine) and PFS-02 (phenylephrine). The partnership is designed to streamline care in clinical settings with ready-to-use prefilled syringes.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CorMedix is a commercial-stage hospital-focused company developing DefenCath (taurolidine/heparin) for catheter-related bloodstream infections in hemodialysis. It is the lead strategic investor in Talphera with a board seat and is negotiating to acquire the company, making it both a direct strategic peer in the hospital/critical care antimicrobial/anticoagulant space and the most relevant potential acquirer.

TypeBroad incumbent
Description

Fresenius is the world's largest dialysis services and products company, with deep involvement in CRRT, hemodialysis equipment, and renal pharmaceuticals. Talphera's CMO previously worked at Fresenius, and Fresenius represents the dominant incumbent across Talphera's renal replacement therapy customer base.

TypeBroad incumbent
Description

Baxter is a major manufacturer of dialysis and CRRT equipment, bloodlines, and replacement fluids used in the extracorporeal circuit. It serves the same hospital ICU customer base that would purchase Niyad and competes broadly in the renal replacement therapy consumables category.

TypeBroad incumbent
Description

B. Braun's Avitum division supplies hemodialysis and CRRT products, including anticoagulation solutions, to hospitals globally. It is a broad incumbent competitor in the renal replacement therapy and perioperative injectable markets that overlap with Niyad and Talphera's pre-filled syringe portfolio.

TypeEmerging player
Description

Spectral Medical is a late-stage clinical company developing PMX (polymyxin B hemoperfusion) for endotoxemic septic shock in the ICU. It shares Talphera's profile as a small-cap hospital/critical care therapeutics developer targeting a defined ICU patient population with a single near-term regulatory catalyst.

TypeEmerging player
Description

Outset Medical develops the Tablo hemodialysis system, marketed for both acute and home dialysis settings. It overlaps with Talphera as a small-cap innovator targeting the renal replacement therapy customer base in hospitals and ICUs.

TypeBroad incumbent
Description

ICU Medical manufactures IV therapy, critical care, and oncology infusion products sold to hospital pharmacies and ICUs. It is a broader incumbent in the medically supervised setting where Talphera's pre-filled syringe and injectable candidates would compete.

TypeEmerging player
Description

AngioDynamics is a small-cap medical device company focused on vascular access, thrombus management, and dialysis products. It is comparable to Talphera as a small-cap medical device/healthcare company selling into hospital and specialty care channels.

9Heparin Sodium generic manufacturers (e.g., Pfizer, Sagent)
TypeBroad incumbent
Description

Heparin is the current standard of care regional anticoagulant for CRRT. Major manufacturers of injectable heparin (Pfizer, Sagent, Fresenius Kabi) represent the entrenched incumbent therapy that Niyad is positioning to displace in heparin-intolerant and high-bleeding-risk patients.

TypeEmerging player
Description

Akebia Therapeutics is a small-cap renal-focused pharmaceutical company (vadadustat for anemia in CKD) where Talphera's Chairman Adrian Adams also serves as Chairman. It is comparable as a publicly traded, late-clinical/early-commercial renal therapeutics company with a hospital/IC channel focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Talphera

Specialty Pharmaceuticalstalphera.com

Talphera is a specialty pharmaceutical company developing therapies for medically supervised settings, with lead candidate Niyad (nafamostat) positioned as the first FDA-approved regional anticoagulant for continuous renal replacement therapy in hospital ICUs. The company also holds royalty rights to the divested DSUVIA product.

What Talphera does

Talphera is a specialty pharmaceutical company that develops and commercializes therapies for medically supervised settings, primarily hospital intensive care units and perioperative environments. Originally founded in 2005 as AcelRx Pharmaceuticals and renamed Talphera in 2023 following the divestiture of its acute pain product DSUVIA, the company has refocused on regional anticoagulation and injectable drug delivery for critically ill patients.

The company's lead product candidate is Niyad (nafamostat mesylate), a lyophilized formulation of a broad-spectrum serine protease inhibitor positioned to be the first FDA-approved regional anticoagulant for the extracorporeal circuit during continuous renal replacement therapy (CRRT) and intermittent hemodialysis. Niyad has received FDA Breakthrough Device Designation and is in a registrational study (NEPHRO CRRT) enrolling 70 patients across up to 14 U.S. hospital ICUs, with PMA submission planned for 2026. Nafamostat's 8-minute half-life enables rapid clearance and predominantly extracorporeal activity, addressing bleeding-risk patients who cannot tolerate heparin. Additional candidates include LTX-608 (a nafamostat product for inflammatory and antiviral indications including COVID-19, DIC, ARDS, and acute pancreatitis) and two pre-filled syringe products (Fedsyra for ephedrine and PFS-02 for phenylephrine) developed in partnership with Laboratoire Aguettant.

Talphera generates revenue primarily through a 15% royalty on commercial net sales of DSUVIA following its 2023 divestiture to Alora Pharmaceuticals (75% on U.S. Department of Defense sales, plus up to $116.5 million in sales-based milestones). The company is pre-commercial on its own pipeline and funds operations through equity financings and royalty monetization, with a recent $29 million private placement led by CorMedix. End customers are anticipated to be hospital ICUs, nephrology departments, and perioperative care providers accessed through hospital pharmacy procurement and group purchasing organizations.

Talphera firmographics

Firmographics
Name
Talphera
Legal name
Talphera, Inc.
Website
https://talphera.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
Talphera is a specialty pharmaceutical company developing therapies for medically supervised settings, with lead candidate Niyad (nafamostat) positioned as the first FDA-approved regional anticoagulant for continuous renal replacement therapy in hospital ICUs. The company also holds royalty rights to the divested DSUVIA product.
Ownership category
akta.pro rank

Talphera industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAHAKAH
Renal Replacement Therapy Consumables (Bloodlines, Filters, Cartridges)
SECONDARYHLAIAIAI
Rare Renal & Nephrology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)

Keywords

  • Regional anticoagulants
  • Renal replacement therapy
  • Specialty pharmaceuticals
  • Critically ill patients
  • Medically supervised settings

Where Talphera is headquartered

Location

Headquarters

HQ city
San Mateo
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Talphera business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. DSUVIA Royalty: Following divestment of DSUVIA to Alora Pharmaceuticals in April 2023, Talphera receives a 15% royalty on commercial net sales, a 75% royalty on net sales to the United States Department of Defense, and up to $116.5 million in sales-based milestone payments.
  2. Niyad (future commercial revenue): Once FDA approved, Niyad would be commercialized as the first FDA-approved regional anticoagulant for the extracorporeal circuit in CRRT, targeting hospitals and ICUs. Currently in late-stage development with PMA submission planned for 2026.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Talphera product offering

Product offering

Core offering

Talphera is a specialty pharmaceutical company developing and commercializing innovative therapies for medically supervised settings. Its lead product candidate, Niyad (nafamostat mesylate), is a lyophilized formulation positioned to become the first FDA-approved regional anticoagulant for the extracorporeal circuit during continuous renal replacement therapy (CRRT) for patients who cannot tolerate heparin or have increased bleeding risk. The company also develops pre-filled syringe products (Fedsyra and PFS-02) for perioperative hypotension and retains royalty rights on the divested DSUVIA product.

Product overview

Talphera is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. The company's portfolio includes Niyad®, its lead product candidate (a lyophilized nafamostat formulation for regional anticoagulation in renal replacement therapy), LTX-608™ (a nafamostat-based candidate for inflammatory and antiviral applications), and two pre-filled syringe candidates (Fedsyra™ and PFS-02) developed in partnership with Laboratoire Aguettant. The company was formerly known as AcelRx Pharmaceuticals and renamed to Talphera following the 2023 divestment of its acute pain product DSUVIA.

Differentiator

Problem solved

Functional benefit

Brands

  • Niyad: A lyophilized formulation of nafamostat mesylate positioned to be the first FDA-approved regional anticoagulant for use in the extracorporeal circuit during continuous renal replacement therapy (CRRT).
  • LTX-608
  • Fedsyra
  • PFS-02
  • DSUVIA

Products and services

  • Niyad (nafamostat mesylate) A lyophilized formulation of nafamostat mesylate positioned to be the first FDA-approved regional anticoagulant for the extracorporeal circuit during continuous renal replacement therapy (CRRT) or intermittent hemodialysis (IHD). It targets hospital intensive care units and nephrology departments treating critically ill patients who cannot tolerate heparin or have increased bleeding risk.
  • LTX-608 A nafamostat-based product candidate being investigated for various indications including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis, leveraging nafamostat's anti-inflammatory and antiviral properties. Regulated as a pharmaceutical.
  • Fedsyra A 10 mL ready-to-use pre-filled syringe of ephedrine hydrochloride in development for the treatment of hypotension during general anesthesia. Developed in partnership with Laboratoire Aguettant to streamline care with waste reduction, time savings, and improved safety.
  • PFS-02 A 10 mL ready-to-use pre-filled syringe of phenylephrine hydrochloride in development for the treatment of hypotension due to vasodilation. Developed in partnership with Laboratoire Aguettant as a ready-to-use alternative to vials and ampules.

Quantifiable outcome

  • Meta-analysis published in 2022 demonstrated significant safety and efficacy improvements over current standards of care for nafamostat use in extracorporeal circuit
  • +2 more outcomes

Companies that use Talphera

Customer profile

Segments2 records

Ideal customer profiles2 records

Talphera technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Talphera partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Laboratoire AguettantsecondaryStrategic or Co-development PartnerPartnership with France-based pharmaceutical company Laboratoire Aguettant for the development of pre-filled syringe product candidates Fedsyra (ephedrine) and PFS-02 (phenylephrine). The partnership is designed to streamline care in clinical settings with ready-to-use prefilled syringes.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Talphera competitors and assessment

Company assessment

Direct peers

  • CorMedix: CorMedix is a commercial-stage hospital-focused company developing DefenCath (taurolidine/heparin) for catheter-related bloodstream infections in hemodialysis. It is the lead strategic investor in Talphera with a board seat and is negotiating to acquire the company, making it both a direct strategic peer in the hospital/critical care antimicrobial/anticoagulant space and the most relevant potential acquirer.

Broad incumbents

  • Fresenius Medical Care: Fresenius is the world's largest dialysis services and products company, with deep involvement in CRRT, hemodialysis equipment, and renal pharmaceuticals. Talphera's CMO previously worked at Fresenius, and Fresenius represents the dominant incumbent across Talphera's renal replacement therapy customer base.
  • Baxter International: Baxter is a major manufacturer of dialysis and CRRT equipment, bloodlines, and replacement fluids used in the extracorporeal circuit. It serves the same hospital ICU customer base that would purchase Niyad and competes broadly in the renal replacement therapy consumables category.
  • B. Braun: B. Braun's Avitum division supplies hemodialysis and CRRT products, including anticoagulation solutions, to hospitals globally. It is a broad incumbent competitor in the renal replacement therapy and perioperative injectable markets that overlap with Niyad and Talphera's pre-filled syringe portfolio.
  • ICU Medical: ICU Medical manufactures IV therapy, critical care, and oncology infusion products sold to hospital pharmacies and ICUs. It is a broader incumbent in the medically supervised setting where Talphera's pre-filled syringe and injectable candidates would compete.
  • Heparin Sodium generic manufacturers (e.g., Pfizer, Sagent): Heparin is the current standard of care regional anticoagulant for CRRT. Major manufacturers of injectable heparin (Pfizer, Sagent, Fresenius Kabi) represent the entrenched incumbent therapy that Niyad is positioning to displace in heparin-intolerant and high-bleeding-risk patients.

Emerging players

  • Spectral Medical: Spectral Medical is a late-stage clinical company developing PMX (polymyxin B hemoperfusion) for endotoxemic septic shock in the ICU. It shares Talphera's profile as a small-cap hospital/critical care therapeutics developer targeting a defined ICU patient population with a single near-term regulatory catalyst.
  • Outset Medical: Outset Medical develops the Tablo hemodialysis system, marketed for both acute and home dialysis settings. It overlaps with Talphera as a small-cap innovator targeting the renal replacement therapy customer base in hospitals and ICUs.
  • AngioDynamics: AngioDynamics is a small-cap medical device company focused on vascular access, thrombus management, and dialysis products. It is comparable to Talphera as a small-cap medical device/healthcare company selling into hospital and specialty care channels.
  • Akebia Therapeutics: Akebia Therapeutics is a small-cap renal-focused pharmaceutical company (vadadustat for anemia in CKD) where Talphera's Chairman Adrian Adams also serves as Chairman. It is comparable as a publicly traded, late-clinical/early-commercial renal therapeutics company with a hospital/IC channel focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Talphera compliance and trust

Trust signal

Compliance1 record

Talphera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Talphera leadership team

Management profile

Number of profiles

Profiles11 records

Talphera funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Talphera M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Talphera

What does Talphera do?

Talphera is a specialty pharmaceutical company developing and commercializing innovative therapies for medically supervised settings. Its lead product candidate, Niyad (nafamostat mesylate), is a lyophilized formulation positioned to become the first FDA-approved regional anticoagulant for the extracorporeal circuit during continuous renal replacement therapy (CRRT) for patients who cannot tolerate heparin or have increased bleeding risk. The company also develops pre-filled syringe products (Fedsyra and PFS-02) for perioperative hypotension and retains royalty rights on the divested DSUVIA product.

Is Talphera a public or private company?

Talphera is a public company. It is classified as public and is currently operating.

When was Talphera founded?

Talphera was founded in 2005. It employs 11 to 50 people.

Where is Talphera based?

Talphera is headquartered in San Mateo, United States, in the North America region.

How does Talphera make money?

Two revenue lines are on record. DSUVIA Royalty is the primary driver. The others are niyad (future commercial revenue).

Who are Talphera's main competitors?

CorMedix is listed as a direct peer. Broad incumbents are Fresenius Medical Care, Baxter International, B. Braun, ICU Medical and Heparin Sodium generic manufacturers (e.g., Pfizer, Sagent). Emerging players are Spectral Medical, Outset Medical, AngioDynamics and Akebia Therapeutics.

Does Talphera have an API?

No public API is recorded for Talphera.

What industry is Talphera in?

Talphera's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAHAKAH, Renal Replacement Therapy Consumables (Bloodlines, Filters, Cartridges), with a secondary code of HLAIAIAI, Rare Renal & Nephrology Disorder Therapies. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaTalphera outlines plan to seek FDA agreement to end NEPHRO enrollment by Dec. 31, 2026, while raising Niyad peak U.S. sales view to over $200MTalphera requested an FDA Sprint Meeting to end NEPHRO enrollment by Dec. 31, 2026, citing slow enrollment due to fewer qualifying patients. The study is over 80% powered, and management raised Niyad's peak U.S. CRRT sales to over $200 million. Topline data are expected within four to six weeks after enrollment closes.Seeking AlphaTalphera, Inc. (TLPH) Q3 2026 Earnings Call TranscriptTalphera reported its third quarter 2026 financial results on November 12, 2026, with CEO Vincent Angotti and CFO Raffi Asadorian speaking. The call included forward-looking statements and a press release with business updates.American Banking and Market NewsWhat Talphera (TLPH) Said on Its Q3 Earnings CallTalphera's Q3 earnings call said it requested FDA agreement to end Niyad study enrollment by Dec. 31, 2026, after a recruiting slowdown. The company raised its peak annual U.S. sales estimate for Niyad in CRRT to over $200 million, with top-line data expected four to six weeks after enrollment ends.Stock TitanTalphera sets Q3 2026 earnings call for Nov. 12Talphera will report its third-quarter 2026 financial results on a conference call on November 12, 2026. The company will also discuss recent business progress during the call.American Banking and Market NewsHead-To-Head Analysis: Inhibikase Therapeutics (NASDAQ:IKT) versus Talphera (NASDAQ:TLPH)Inhibikase Therapeutics beats Talphera on 9 of 14 factors, including a stronger consensus rating and higher upside. Inhibikase's beta is 0.89 versus Talphera's 0.67, and its price-to-earnings ratio is lower. Analysts favor Inhibikase, citing higher probable upside.American Banking and Market NewsComparing Talphera (NASDAQ:TLPH) & ANI Pharmaceuticals (NASDAQ:ANIP)ANI Pharmaceuticals and Talphera are compared on valuation, earnings, institutional ownership, profitability, and analyst ratings. ANI has higher revenue and earnings, but Talphera shows higher upside potential. ANI beats Talphera on 11 of 14 factors.Defense WorldInhibikase Therapeutics (NASDAQ:IKT) vs. Talphera (NASDAQ:TLPH) Head-To-Head ComparisonInhibikase Therapeutics and Talphera are compared on profitability, institutional ownership, and analyst ratings. Inhibikase beats Talphera on 9 of 14 factors, with a consensus price target of $5.40 versus $3.00. Inhibikase has lower revenue but higher earnings and a lower P/E ratio.American Banking and Market NewsReviewing Talphera (NASDAQ:TLPH) & Incannex Healthcare (NASDAQ:IXHL)Talphera and Incannex Healthcare are compared on valuation, earnings, and analyst ratings. Talphera has higher institutional ownership (37.7% vs 0.4%) and lower volatility, while Incannex has higher upside potential. Talphera beats Incannex on 8 of 13 factors.YahooTalphera (TLPH) Upgraded to Buy: Here's What You Should KnowTalphera (TLPH) was upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates. The rating reflects improved earnings outlook, which could drive buying pressure and a higher stock price. The Zacks system tracks EPS estimates to gauge near-term price movements.Ticker ReportTalphera (NASDAQ:TLPH) vs. Lexaria Bioscience (NASDAQ:LEXX) Head-To-Head ComparisonTalphera and Lexaria Bioscience are compared on valuation, risk, and analyst ratings. Lexaria has higher revenue and earnings but a lower upside target, while Talphera trades at a lower P/E ratio. Talphera beats Lexaria on 8 of 13 factors.